Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

$Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease$

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

by Or, Reuven , Szer, Jeff , Butler, Jason , Mahuzier, Bruyère , Niederwieser, Dietger , Gandhi, Kunal K , Zeiser, Robert , von Bubnoff, Nikolas , Xu, Judith , Wagner, Eva M , Mohty, Mohamad , Socié, Gérard , Zuckerman, Tsila , Wilke, Celine

in Acute Disease / Adolescent / Adult / Aged / Blood diseases / Cancer therapies / Child / Cytomegalovirus / Drug dosages / Enzyme inhibitors / Female / Glucocorticoids / Glucocorticoids - therapeutic use / Graft versus host disease / Graft vs Host Disease - drug therapy / Graft-versus-host reaction / Granulocytes / Hematological diseases / Humans / Infections / Inhibitor drugs / Janus kinase / Janus kinase 2 / Janus Kinase Inhibitors - adverse effects / Janus Kinase Inhibitors - therapeutic use / Male / Middle Aged / Neutrophils / Pyrazoles - adverse effects / Pyrazoles - therapeutic use / Stem cell transplantation / Stem Cell Transplantation - adverse effects / Thrombocytopenia / Thrombocytopenia - chemically induced / Transplantation, Homologous / Young Adult

2020

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

2020

Confirm

Do you wish to request the book?

$Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease$

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

2020

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

$Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease$

Journal Article

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

Or, Reuven,

Szer, Jeff,

Butler, Jason,

Mahuzier, Bruyère,

Niederwieser, Dietger,

Gandhi, Kunal K,

Zeiser, Robert,

von Bubnoff, Nikolas,

Xu, Judith,

Wagner, Eva M,

Mohty, Mohamad,

Socié, Gérard,

Zuckerman, Tsila,

Wilke, Celine

2020

Overview

When acute GVHD is refractory to glucocorticoids, no consensus exists on the best therapy. In a phase 3, randomized trial, ruxolitinib led to a response in 62% of patients at day 28 and in 40% at day 56, as compared with 39% at day 28 and 22% at day 56 with the investigator’s choice of therapy.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Acute Disease

/ Adolescent

/ Adult

/ Aged

/ Blood diseases

/ Cancer therapies

/ Child